US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will present an overview of the company at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 4:00 p.m. eastern time at the Sofitel New York.
To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACT for investors and media: [email protected] 650-635-7000
